LLNS, TBWA get DTC impresario CEO

Share this article:
LLNS and TBWA Worldhealth named Anne Devereux CEO.                       Devereux, formerly head of Omnicom sibling BBDO’s New York DTC practice, will serve as operational head of LLNS, replacing Al Nickel as CEO. Nickel continues as chairman of the network, while Steven Wice continues as president. Devereux will is also charged with coordinating the global agency network that comprises TBWA Worldhealth, which draws on agencies throughout Omnicom’s Diversified Agency Services (DAS) group. Serving as co-chairs of TBWA Worldhealth are Robert LePlae, president for TBWA North America, and Nick Baum, his counterpart for Western Europe. Taking over as head of DTC at BBDO New York will be Devereux’s deputy, Ray Hilton, who becomes EVP and senior account director. Under Devereux, the agency produced high-profile consumer campaigns for brands such as Schering-Plough’s Nasonex and GSK/Schering’s Levitra.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...